MNMD
Price
$13.65
Change
+$1.74 (+14.61%)
Updated
Oct 17 closing price
Capitalization
1.04B
25 days until earnings call
Intraday Buy/Sell Signals
RIGL
Price
$27.94
Change
-$0.17 (-0.60%)
Updated
Oct 17 closing price
Capitalization
501.17M
Intraday Buy/Sell Signals
Interact to see
Advertisement

MNMD vs RIGL

Header iconMNMD vs RIGL Comparison
Open Charts MNMD vs RIGLBanner chart's image
Mind Medicine (MindMed)
Price$13.65
Change+$1.74 (+14.61%)
Volume$3.79M
Capitalization1.04B
Rigel Pharmaceuticals
Price$27.94
Change-$0.17 (-0.60%)
Volume$383.57K
Capitalization501.17M
MNMD vs RIGL Comparison Chart in %
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. RIGL commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a Hold and RIGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (MNMD: $13.65 vs. RIGL: $27.94)
Brand notoriety: MNMD and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 241% vs. RIGL: 55%
Market capitalization -- MNMD: $1.04B vs. RIGL: $501.17M
MNMD [@Biotechnology] is valued at $1.04B. RIGL’s [@Biotechnology] market capitalization is $501.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 1 green FA rating(s).

  • MNMD’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 1 green, 4 red.
According to our system of comparison, RIGL is a better buy in the long-term than MNMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 5 TA indicator(s) are bullish while RIGL’s TA Score has 5 bullish TA indicator(s).

  • MNMD’s TA Score: 5 bullish, 4 bearish.
  • RIGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both MNMD and RIGL are a good buy in the short-term.

Price Growth

MNMD (@Biotechnology) experienced а +15.58% price change this week, while RIGL (@Biotechnology) price change was -0.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

MNMD is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($1.04B) has a higher market cap than RIGL($501M). MNMD YTD gains are higher at: 96.121 vs. RIGL (66.112). RIGL has higher annual earnings (EBITDA): 109M vs. MNMD (-110.19M). MNMD has more cash in the bank: 183M vs. RIGL (108M). MNMD has less debt than RIGL: MNMD (41.2M) vs RIGL (61M). RIGL has higher revenues than MNMD: RIGL (268M) vs MNMD (0).
MNMDRIGLMNMD / RIGL
Capitalization1.04B501M207%
EBITDA-110.19M109M-101%
Gain YTD96.12166.112145%
P/E RatioN/A5.15-
Revenue0268M-
Total Cash183M108M169%
Total Debt41.2M61M68%
FUNDAMENTALS RATINGS
MNMD vs RIGL: Fundamental Ratings
MNMD
RIGL
OUTLOOK RATING
1..100
8251
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
9087
SMR RATING
1..100
988
PRICE GROWTH RATING
1..100
3841
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
4050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (38) in the null industry is in the same range as RIGL (53) in the Biotechnology industry. This means that MNMD’s stock grew similarly to RIGL’s over the last 12 months.

RIGL's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as MNMD (90) in the null industry. This means that RIGL’s stock grew similarly to MNMD’s over the last 12 months.

RIGL's SMR Rating (8) in the Biotechnology industry is significantly better than the same rating for MNMD (98) in the null industry. This means that RIGL’s stock grew significantly faster than MNMD’s over the last 12 months.

MNMD's Price Growth Rating (38) in the null industry is in the same range as RIGL (41) in the Biotechnology industry. This means that MNMD’s stock grew similarly to RIGL’s over the last 12 months.

MNMD's P/E Growth Rating (100) in the null industry is in the same range as RIGL (100) in the Biotechnology industry. This means that MNMD’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDRIGL
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGIRX98.65N/A
N/A
JPMorgan U.S. GARP Equity R5
FLACX87.12N/A
N/A
Fidelity Advisor Stock Sel C
IPOCX18.14N/A
N/A
Macquarie Systematic Em Mkts Eq C
LSHCX24.74N/A
N/A
Kinetics Spin-Off and Corp Rest Adv C
MYINX9.93-0.03
-0.30%
NYLI WMC International Rsrch Eq Inv Cl

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
+14.61%
ATAI - MNMD
50%
Loosely correlated
+17.70%
RXRX - MNMD
49%
Loosely correlated
-7.86%
OCUL - MNMD
48%
Loosely correlated
-2.95%
LABFF - MNMD
47%
Loosely correlated
N/A
VRDN - MNMD
47%
Loosely correlated
+5.22%
More